Literature DB >> 24435758

Understanding the beneficial effects of doxycycline on the dystrophic phenotype of the mdx mouse.

Juliano Alves Pereira1, Cintia Yuri Matsumura, Elaine Minatel, Maria Julia Marques, Humberto Santo Neto.   

Abstract

INTRODUCTION: The purpose of this study was to better understand the beneficial effects of doxycycline on the dystrophic muscles of the mdx mouse.
METHODS: Doxycycline (DOX) was administered for 36 days, starting on postnatal day 0, via drinking water. Untreated mdx mice received plain water for the same period and served as a control group.
RESULTS: DOX decreased the levels of metalloproteinase-9 and tumor necrosis factor-alpha in the biceps brachii and diaphragm of the mdx mice. It also reduced the total amount of calcium in the muscles studied, concomitant with an increase in the levels of calsequestrin 1.
CONCLUSIONS: The results show that DOX can affect factors that are important in dystrophic pathogenesis and highlight its potential as a readily accessible therapy in clinical trials for treatment of Duchenne muscular dystrophy.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  DMD; TNF-α; calsequestrin 1; doxycycline; mdx; metalloproteinase-9

Mesh:

Substances:

Year:  2014        PMID: 24435758     DOI: 10.1002/mus.24177

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  2 in total

Review 1.  Therapeutic potential of matrix metalloproteinases in Duchenne muscular dystrophy.

Authors:  Yuji Ogura; Marjan M Tajrishi; Shuichi Sato; Sajedah M Hindi; Ashok Kumar
Journal:  Front Cell Dev Biol       Date:  2014-04-01

2.  Doxycycline Inhibits IL-17-Stimulated MMP-9 Expression by Downregulating ERK1/2 Activation: Implications in Myogenic Differentiation.

Authors:  Hristina Obradović; Jelena Krstić; Tamara Kukolj; Drenka Trivanović; Ivana Okić Đorđević; Slavko Mojsilović; Aleksandra Jauković; Gordana Jovčić; Diana Bugarski; Juan Francisco Santibañez
Journal:  Mediators Inflamm       Date:  2016-11-30       Impact factor: 4.711

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.